Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab plus VTD in first-line transplant-eligible newly diagnosed multiple myeloma
NL-OMON55990Phase 3Recruiting
- Sponsor
- Intergroupe Francophone du Myelome (IFM)
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daratumumab in multiple myeloma (MM) (2 arms), sponsored by Intergroupe Francophone du Myelome (IFM). Primary endpoints: Stringent complete response rate after consolidation therapy and Progression-free survival after maintenance therapy. Started Dec 2015; status: recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON55990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55990.